The Use of ω-3 Poly-Unsaturated Fatty Acids in Heart Failure: A Preferential Role in Patients with Diabetes
- 30 May 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 26 (4), 311-320
- https://doi.org/10.1007/s10557-012-6397-x
Abstract
To review the evidence for a beneficial effect of ω-3 PUFAs in heart failure (HF) and its co-morbidities, their possible preferential effect in diabetes and the potential mechanism for their benefit. We summarize the clinical studies which investigated the use of ω-3 PUFAs in patients with HF with an emphasis on diabetes. We briefly summarize the evidence for an effect of ω-3 PUFAs in patients with coronary artery disease (CAD), atrial fibrillation (AF) and ventricular arrhythmias. We also discuss the proposed mechanisms of ω-3 PUFA action in cardiovascular diseases. While there is emerging evidence for a beneficial effect of ω-3 PUFA supplementation in patients with HF, the evidence for other indications have been variable and conflicting. In HF patients with diabetes, ω-3 PUFAs may have a preferential therapeutic benefit. Randomized controlled trials did not show considerable beneficial effects of ω-3 PUFAs in other conditions such as CAD and AF. In a diabetic and insulin-resistant state, ω-3 PUFAs bind to the G-protein coupled receptor, GPR120, resulting in reduced cytokine production from inflammatory macrophages and improved signaling in adipocytes, leading to a reduction in insulin resistance. There is promising evidence showing that use of ω-3 PUFA supplementation improves clinical outcomes of HF patients with diabetes. Further clinical trials are needed in this regard.Keywords
This publication has 89 references indexed in Scilit:
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsThe New England Journal of Medicine, 2011
- n–3 Fatty Acids and Cardiovascular Events after Myocardial InfarctionThe New England Journal of Medicine, 2010
- GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing EffectsCell, 2010
- HFSA 2010 Comprehensive Heart Failure Practice GuidelineJournal of Cardiac Failure, 2010
- Dietary n−6 and n−3 polyunsaturated fatty acids: From biochemistry to clinical implications in cardiovascular preventionBiochemical Pharmacology, 2009
- Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunctionCardiovascular Research, 2008
- Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Adiponectin actions in the cardiovascular systemCardiovascular Research, 2007
- Effect of Fish Oil on Ventricular Tachyarrhythmia and Death in Patients With Implantable Cardioverter DefibrillatorsJama-Journal Of The American Medical Association, 2006
- Fish Oil Supplementation and Risk of Ventricular Tachycardia and Ventricular Fibrillation in Patients With Implantable DefibrillatorsJama-Journal Of The American Medical Association, 2005